Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Net Loss from Continuing Operations $19.9 million in Q2 2025, compared to $26.2 million in Q2 2024, reflecting a decrease of $6.3 million year-over-year. The reduction was due to lower research and development expenses and general and administrative expenses.
Research and Development Expenses $12.9 million in Q2 2025, compared to $15.8 million in Q2 2024, reflecting a decrease of $2.9 million year-over-year. This was driven by lower costs related to the completion of the SER-155 Phase Ib study, lower personnel expenses, and a decrease in platform investments.
General and Administrative Expenses $10.3 million in Q2 2025, compared to $13.1 million in Q2 2024, reflecting a decrease of $2.8 million year-over-year. The reduction was primarily due to lower personnel and related expenses, including IT-related costs.
Cash and Cash Equivalents $45.4 million as of June 30, 2025. Additionally, the company received a $25 million installment payment from Nestlé in July 2025. The cash position reflects the company's ability to fund operations into the first quarter of 2026, supported by cost reduction actions.
Trade with 70% Backtested Accuracy
Analyst Views on MCRB
About MCRB
About the author
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction
FDA Feedback on SER-155: Seres Therapeutics received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in adults undergoing stem cell transplants, which will aid in finalizing the protocol.
Workforce Reduction and Financial Outlook: The company is reducing its workforce by approximately 25%, which is expected to incur cash payments of $1.0 - $1.4 million in Q4 2025, while extending its cash runway into the second quarter of 2026.
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.
Cost-Cutting Measures: Seres Therapeutics plans to reduce its workforce by about 25% to trim operating costs, which is expected to extend its cash runway into the second quarter of 2026.
SER-155 Study Development: Following positive FDA feedback, the company aims to finalize the Phase 2 study protocol for SER-155, targeting bloodstream infections in adults undergoing stem cell transplants, while seeking capital to support this and other biotherapeutic developments.
Everything You Should Know About Seres Therapeutics (MCRB) Upgrade to Buy Rating
Zacks Rank Upgrade: Seres Therapeutics (MCRB) has been upgraded to a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Seres Therapeutics is positioned for potential near-term gains, as it falls within the top 20% of Zacks-covered stocks based on these revisions.
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Biotech Stocks Surge: Several biotech and medical technology stocks experienced significant gains in after-hours trading, driven by earnings optimism, clinical trial progress, and speculative positioning, with notable movers including Seres Therapeutics and TransMedics.
Key Developments: TransMedics received FDA approval for its heart trial, while Capricor announced a milestone in its vaccine trial. Other companies like Karyopharm and Coya Therapeutics saw stock rebounds despite lacking specific news catalysts, indicating investor anticipation for future developments.
Market Volatility: Stocks such as Meihua International and Jin Medical showed notable price movements without specific news, reflecting technical rebounds and investor positioning in a volatile market environment.
Earnings Reports and Guidance: TransMedics raised its revenue guidance for 2025, projecting significant growth, while other companies are preparing for upcoming earnings reports and trial milestones, contributing to the overall market momentum in the biotech sector.
Robinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Robinhood's Market Movement: Robinhood Markets, Inc. shares surged 7.4% in pre-market trading after being announced as a replacement for Caesars Entertainment in the S&P 500, effective September 22.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Eightco Holdings (up 142.1%), Gyrodyne (up 82.1%), and Forward Industries (up 78.8%).
Pre-Market Losers: Citius Oncology experienced a 25% drop, while MEI Pharma and CNFinance also saw declines of 19.3% and 18.8%, respectively, in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances, highlighting both significant gainers and losers in the pre-market trading session.
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction
FDA Feedback on SER-155: Seres Therapeutics received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in adults undergoing stem cell transplants, which will aid in finalizing the protocol.
Workforce Reduction and Financial Outlook: The company is reducing its workforce by approximately 25%, which is expected to incur cash payments of $1.0 - $1.4 million in Q4 2025, while extending its cash runway into the second quarter of 2026.
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.
Cost-Cutting Measures: Seres Therapeutics plans to reduce its workforce by about 25% to trim operating costs, which is expected to extend its cash runway into the second quarter of 2026.
SER-155 Study Development: Following positive FDA feedback, the company aims to finalize the Phase 2 study protocol for SER-155, targeting bloodstream infections in adults undergoing stem cell transplants, while seeking capital to support this and other biotherapeutic developments.
Everything You Should Know About Seres Therapeutics (MCRB) Upgrade to Buy Rating
Zacks Rank Upgrade: Seres Therapeutics (MCRB) has been upgraded to a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Seres Therapeutics is positioned for potential near-term gains, as it falls within the top 20% of Zacks-covered stocks based on these revisions.
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Biotech Stocks Surge: Several biotech and medical technology stocks experienced significant gains in after-hours trading, driven by earnings optimism, clinical trial progress, and speculative positioning, with notable movers including Seres Therapeutics and TransMedics.
Key Developments: TransMedics received FDA approval for its heart trial, while Capricor announced a milestone in its vaccine trial. Other companies like Karyopharm and Coya Therapeutics saw stock rebounds despite lacking specific news catalysts, indicating investor anticipation for future developments.
Market Volatility: Stocks such as Meihua International and Jin Medical showed notable price movements without specific news, reflecting technical rebounds and investor positioning in a volatile market environment.
Earnings Reports and Guidance: TransMedics raised its revenue guidance for 2025, projecting significant growth, while other companies are preparing for upcoming earnings reports and trial milestones, contributing to the overall market momentum in the biotech sector.
Robinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Robinhood's Market Movement: Robinhood Markets, Inc. shares surged 7.4% in pre-market trading after being announced as a replacement for Caesars Entertainment in the S&P 500, effective September 22.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Eightco Holdings (up 142.1%), Gyrodyne (up 82.1%), and Forward Industries (up 78.8%).
Pre-Market Losers: Citius Oncology experienced a 25% drop, while MEI Pharma and CNFinance also saw declines of 19.3% and 18.8%, respectively, in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances, highlighting both significant gainers and losers in the pre-market trading session.
